{"type":"trials","record":{"id":87102,"source_id":"isrctn","external_id":"ISRCTN10012824","title":"Light-Touch Study","brief_summary":"For patients with wet age-related macular degeneration (AMD) that switch to faricimab, it is not known how frequently the injections should be given after switching. This study will determine whether a single treatment (a ‘Light Touch’) at the beginning followed by a personalised treatment interval is as clinically effective as an intensive period of four monthly treatments (an ‘induction phase’) followed by personalised treatment intervals. The primary objective hypothesises that the intervention “Light Touch” arm will be non-inferior to the standard of care (SoC) \"Induction Phase\" arm in terms of visual outcome at an average of Week 52 and Week 56. The secondary objectives of the Light Touch Trial aim to explore additional outcomes beyond comparing change in visual acuity. Specifically, the trial seeks to answer the following questions: 1. Visual acuity improvements: how many patients experience improvements in their vision after switching to faricimab, and how significant are these improvements? 2. Avoiding vision loss: how many patients manage to avoid losing vision during the trial? 3. Vision quality over time: how consistent is the treatment response over time in terms of vi…","overall_status":"Recruiting","phases":["Phase III"],"study_type":"Interventional","sponsor":"Moorfields Eye Hospital","enrollment":230,"countries":["United Kingdom"],"start_date":"2024-11-10","completion_date":"2027-11-30","last_update_date":"2025-10-24","source_url":"https://www.isrctn.com/ISRCTN10012824","editorial_summary":"A registered Phase III study indexed because it matched monitored longevity research terms. Registry status: Recruiting. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T03:46:39.792962+00:00","last_seen_at":"2026-09-25T03:46:39.551+00:00","metadata":{"sex":"All","age_range":"Adult","comparator":null,"attribution":"Source: ISRCTN ISRCTN10012824; retrieved 2026-09-25","interventions":["Faricimab","Drug"],"reuse_license":"Registry contribution CC BY 4.0; generated metadata CC0","registry_source":"ISRCTN","outcome_measures":["Change in best corrected visual acuity (BCVA) from baseline to an average of Week 52 and Week 56, as measured by the Ea…","Measured at Baseline, Week 20 and Week 56: 1. Efficacy on additional BCVA outcomes 2. Efficacy of anatomic outcome meas…"],"design_description":"Interventional","source_has_results":false},"controlled_terms":["Neovascular age-related macular degeneration","Patients with nAMD in at least one eye which were previously treated with anti-angiogenic therapy that would not allow…","Faricimab","Drug"],"relevance_confidence":100,"source_quality_score":98,"freshness_score":85,"publication_state":"published","match_explanation":"Abstract contains controlled term: age-related macular degeneration.","quality_checked_at":"2026-09-25T03:46:42.633202+00:00","duplicate_cluster_key":"id:isrctn10012824","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2024-11-10 to 2027-11-30","comparator":null,"confidence":"structured-source","population":"All · Adult","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T03:46:39.558Z","intervention":["Faricimab","Drug"],"participants":230,"study_design":"Interventional","subject_scope":"Human clinical study registration","evidence_stage":"Phase III","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Change in best corrected visual acuity (BCVA) from baseline to an average of Week 52 and Week 56, as measured by the Ea…","Measured at Baseline, Week 20 and Week 56: 1. Efficacy on additional BCVA outcomes 2. Efficacy of anatomic outcome meas…"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"vision-aging","is_published":true,"match_reasons":["Abstract contains controlled term: age-related macular degeneration.","Source terminology contains: age-related macular degeneration.","Abstract supplies longevity context: age-related.","Study type is explicitly identified as Interventional."],"matched_fields":["abstract","controlled terminology","abstract context","study type"],"relevance_score":100,"intelligence_topics":{"name":"Vision ageing","slug":"vision-aging"}}],"content_sources":{"name":"ISRCTN Registry","homepage_url":"https://www.isrctn.com/"}},"canonical_url":"https://www.immortal.life/trials/87102","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}